Lorazepam (Ativan) is a Schedule IV benzodiazepine used for anxiety disorders, acute seizures, alcohol withdrawal, and procedural sedation. It works by positively modulating GABA-A receptors, enhancing the inhibitory effect of GABA in the CNS. A key pharmacological feature is that lorazepam has no active metabolites — it undergoes direct glucuronidation — making it more predictable than longer-acting benzodiazepines like diazepam. Physical dependence develops with regular use; abrupt discontinuation can cause life-threatening withdrawal seizures.
Lorazepam
Uses & FDA Indications
Lorazepam is one of the most widely used benzodiazepines in both outpatient and inpatient settings. Its intermediate duration of action and absence of active metabolites make it particularly useful in clinical situations where a predictable offset is important, such as procedural sedation and ICU sedation.
FDA-approved indications include: anxiety disorders (short-term management of anxiety symptoms), preanesthetic medication (to produce sedation, anxiolysis, and anterograde amnesia prior to procedures), and status epilepticus (IV formulation). Off-label uses include alcohol withdrawal syndrome, acute agitation, chemotherapy-induced nausea, and insomnia.
In emergency medicine and critical care, IV lorazepam is the preferred first-line benzodiazepine for status epilepticus according to major guidelines. Its pharmacokinetic advantages over diazepam in this setting include no need for redistribution to fatty tissue after the initial dose and a more sustained CNS effect relative to its plasma half-life.
How It Works
Lorazepam is a positive allosteric modulator of the GABA-A receptor — the primary inhibitory ligand-gated ion channel in the CNS. It binds to a specific site on the GABA-A receptor (the benzodiazepine binding site, distinct from where GABA itself binds), increasing the frequency of chloride channel opening in response to GABA. The result is enhanced inhibitory neurotransmission throughout the brain.
This mechanism produces the core benzodiazepine effects: anxiolysis, sedation, anticonvulsant activity, muscle relaxation, and anterograde amnesia. All benzodiazepines share this mechanism; differences in clinical effects are largely determined by pharmacokinetic factors such as half-life, lipophilicity, and presence of active metabolites.
A key pharmacokinetic advantage of lorazepam: unlike diazepam and chlordiazepoxide, lorazepam does not undergo hepatic CYP450 metabolism. It is conjugated directly to a glucuronide (phase II metabolism) and renally excreted. This makes lorazepam one of the safest benzodiazepines in patients with liver disease, and it has fewer CYP450-based drug interactions than diazepam.
PHYSICAL DEPENDENCE AND WITHDRAWAL: Regular use of lorazepam for more than a few weeks leads to physical dependence. Abrupt discontinuation can cause life-threatening withdrawal seizures. Benzodiazepine withdrawal shares a similar danger profile with alcohol withdrawal — both work on GABA-A receptors and both can cause fatal seizures upon abrupt discontinuation. Never stop lorazepam abruptly after prolonged use without medical supervision and a taper plan.
Side Effects
Common
- Sedation / drowsiness — the most prominent effect; impairs driving and psychomotor function
- Anterograde amnesia — impairs formation of new memories during drug effect; therapeutically useful pre-procedure, problematic otherwise
- Ataxia / dizziness / impaired coordination — particularly at higher doses
- Cognitive impairment — slowed thinking, reduced concentration, especially with chronic use
- Paradoxical reactions — in some patients (especially children and elderly): increased anxiety, agitation, aggression, disinhibition
Serious
- Respiratory depression — especially when combined with opioids, alcohol, or other CNS depressants; can be fatal. IV lorazepam requires resuscitation equipment availability.
- Physical dependence and withdrawal seizures — develop with regular use; withdrawal after prolonged use is medically dangerous
- Falls and fractures — impaired balance and sedation increase fall risk, especially in elderly; Beers Criteria lists all benzodiazepines as potentially inappropriate in older adults
- Rebound anxiety and insomnia — return of symptoms, often more intensely, upon dose reduction or discontinuation
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Opioids (oxycodone, hydrocodone, fentanyl, morphine) | FDA black box warning: combined use causes profound CNS and respiratory depression; markedly increases risk of fatal overdose. | High — black box warning; use only when no alternative exists; minimize doses and duration |
| Alcohol | Additive CNS and respiratory depression; alcohol also increases GABA-A activity synergistically with benzodiazepines. | High — counsel patients to avoid alcohol completely during lorazepam use |
| Other CNS Depressants (sleep aids, antihistamines, antipsychotics, muscle relaxants) | Additive sedation and respiratory depression risk. | Moderate-High — caution; reduce doses if combination unavoidable |
| Valproate | Valproate inhibits lorazepam glucuronidation, increasing lorazepam plasma levels by up to 40%. | Moderate — monitor for enhanced sedation; dose reduction of lorazepam may be needed |
| Probenecid | Inhibits lorazepam glucuronidation, slowing clearance and prolonging effects. | Moderate — reduce lorazepam dose if combination required |
Warnings & Contraindications
Contraindications
- Acute narrow-angle glaucoma
- Hypersensitivity to lorazepam or other benzodiazepines
- Severe respiratory insufficiency (relative contraindication; require resuscitation backup for IV use)
- Pregnancy (Category D — benzodiazepine exposure associated with neonatal withdrawal and potential teratogenicity)
Black Box Warning: Opioid Combination
The FDA requires a black box warning that concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. This combination should be reserved for patients for whom alternative treatment options are inadequate; the lowest effective doses should be used for the shortest duration, with monitoring for signs of respiratory depression.
Dependence and Scheduled Status
Lorazepam is a Schedule IV controlled substance under the DEA Controlled Substances Act, indicating recognized abuse potential. Tolerance to the sedative and anxiolytic effects develops with regular use. Physical dependence — reflected in a withdrawal syndrome upon discontinuation — is expected with regular use beyond 4–6 weeks. Psychological dependence (craving, drug-seeking) also occurs. Benzodiazepines should generally be prescribed for the shortest effective duration.
Use in Elderly
All benzodiazepines are listed on the American Geriatrics Society Beers Criteria as potentially inappropriate medications in adults 65 and older, due to increased cognitive impairment, delirium, falls, fractures, and motor vehicle accidents in this population. Lorazepam is considered relatively better-tolerated among benzodiazepines in the elderly (due to no active metabolites and less accumulation than diazepam), but it remains associated with significant harms compared to non-benzodiazepine alternatives.
Check for respiratory depression risk or other interactions with lorazepam and opioids.
Check Drug Interactions →Frequently Asked Questions
Why does lorazepam have no active metabolites?
Unlike diazepam, which is metabolized through the liver's CYP450 system into active compounds like desmethyldiazepam that persist for days, lorazepam undergoes direct glucuronidation — a simpler phase II metabolic process that converts it directly into an inactive glucuronide conjugate. This means lorazepam produces no pharmacologically active breakdown products, leading to a more predictable offset of action and making it safer in patients with liver disease, the elderly, and those on multiple medications that affect CYP450 enzymes.
Can lorazepam cause withdrawal seizures?
Yes — abrupt discontinuation of lorazepam after physical dependence has developed can cause life-threatening withdrawal seizures. Benzodiazepine withdrawal is one of the few drug withdrawal syndromes that can be fatal (along with alcohol withdrawal). Because lorazepam has a relatively short half-life, withdrawal symptoms can emerge quickly — within 24–48 hours — after abrupt stopping. Patients who have been on benzodiazepines for more than a few weeks require a slow taper, typically converting to a longer-acting benzodiazepine like diazepam to facilitate a gradual withdrawal.
How is lorazepam different from diazepam?
Lorazepam and diazepam are both benzodiazepines but differ in several clinically important ways. Lorazepam has a shorter half-life (10–20 hours) vs. diazepam's 20–100 hours; lorazepam has no active metabolites while diazepam produces desmethyldiazepam (half-life 36–200 hours). Lorazepam undergoes glucuronidation (not affected by liver disease or CYP450 drug interactions), while diazepam requires hepatic CYP2C19/3A4 metabolism. For IV use, lorazepam is the preferred benzodiazepine for acute seizure management due to its reliable brain penetration; diazepam has faster onset but shorter CNS duration. In elderly patients, lorazepam is generally preferred over diazepam due to less accumulation risk.